NEW YORK, NY (March 30, 2016) – A global study released today by InterbrandHealth identifies the biopharma companies that are addressing healthcare professionals’ (HCPs), payers’, and policymakers’ needs. A commitment to brand is a promise to address healthcare challenges and meet the needs of these healthcare professionals.
The study examines what value means to HCPs and illustrates the influence the corporate brand has in conveying that value. It reveals how leading companies are beginning to deliver on what matters to HCPs.
Looking to the future, healthcare professionals desire a commitment to innovative healthcare solutions that go “beyond the pill.” As a result, leading biopharma companies are adapting their business models, increasing transparency, exploring nontraditional solutions in areas like digital therapies, and ramping up their corporate citizenship activities.
“Biopharma is at a pivotal moment, and the time for change is now,” said Jane Parker, InterbrandHealth’s CEO.
Dr. Ronnie Hershman, a cardiologist affiliated with NYU Langone Long Island Cardiac Care and the CEO of HealthEffect, LLC, noted, “The biopharma industry has relied on blockbuster drugs for a long time, but healthcare is changing, and what physicians need has changed. Biopharma companies need to shift and think about what else they can offer.”
Best Pharma Brands ranks these leading companies by qualifying the industry’s definition of value through brand, then quantifying the corporate brand’s contribution to business performance. The ranking identifies the 10 most valuable biopharma brands. In total, these 10 brands represent approximately USD $129 billion in brand value. Pfizer and the Roche Group secure the #1 and #2 positions on the ranking.
*The ranking and brand value for each organization is outlined below
#1 Pfizer (USD $19.985 billion)
#2 Roche Group (USD $15.479 billion)
#3 Merck & Co., Inc., Kenilworth, N.J., U.S.A. (USD $13.880 billion) [Note: MSD outside of the United States & Canada]
#4 Janssen: Pharmaceutical Companies of Johnson & Johnson (USD $13.866 billion)
#5 Novartis (USD $13.496 billion)
#6 Amgen (USD $13.461 billion)
#7 Gilead Sciences (USD $13.361 billion)
#8 Novo Nordisk (USD $10.206 billion)
#9 AstraZeneca (USD $8.123 billion)
#10 GSK (USD $6.778 billion)
Best Pharma Brands also sets an important industry benchmark by highlighting the need for biopharma companies to change how they interact with the market and meet the needs of the healthcare community.
Parker commented that “these 10 biopharma brands are embracing a strategy that is somewhat new to the health and life sciences sector: they are effectively leveraging their corporate brands and, in doing so, they are growing their businesses, fueling innovation, and developing meaningful solutions for patients on a global scale.”
Best Pharma Brands is powered by global research data, feedback from HCPs, and data-driven insights. The underlying methodology mirrors Interbrand’s Best Global Brands, which demonstrates that strong brands can withstand market volatility and are more likely to outperform key financial indices like the S&P 500.
To be considered, biopharma brands must have a global presence, generate revenue from the sale of prescription medicines, report the ratio of revenues generated from sales of prescription medicines, possess a strong pipeline of potential future prescription medicines, have awareness among HCPs, and serve as the primary external-facing manufacturer brand.
Please visit BestPharmaBrands.com to request a download of the report. To join the conversation on social media, use the hashtag #BestPharmaBrands.
About Best Pharma Brands
Best Pharma Brands is InterbrandHealth’s inaugural top 10 ranking that quantifies the corporate brand’s contribution to business performance in the biopharma industry.
Best Pharma Brands is powered by Interbrand’s International Organization for Standardization (ISO)–certified Brand Valuation methodology, which quantifies the measurable financial impact that a company’s brand has on its overall business performance.
Best Pharma Brands reflects HCPs’ current perceptions of brand value, measured through a global online survey. The report focuses on the prescription portion of a biopharma company’s total revenue. Other revenue sources, including consumer health, over-the-counter products, medical device sales, diagnostics, and animal health are excluded from the analysis.
In addition to the ranking and supporting commentary, the report examines industry trends and provides data-driven insights on topics such as the impact of the corporate brand in an adoption decision, mergers and acquisitions, and corporate citizenship. The report clearly outlines how corporate brand, when leveraged, can generate significant value for a business. It sets an important industry benchmark and highlights the potential for future change.